Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (DE:GE91)
STUTTGART:GE91
Genmab (GE91) Stock Price & Analysis
2 Followers
GE91 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€24.40 - €39.40
Previous Close€26.8
Volume0.00
Average Volume (3M)80.00
Market Cap
$17.91B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Beta0.48
Next Earnings
May 02, 2024EPS Estimate
€0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume80
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€37.11Price Target Upside36.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Genmab News
PremiumCompany Announcements
Genmab Advances Share Buy-back Program
PremiumCompany Announcements
Genmab Reports Strong Q1 Sales of DARZALEX
PremiumCompany Announcements
Genmab Advances Share Buy-back Program
PremiumCompany Announcements
Genmab Advances Share Buy-back ProgramBulls Say, Bears Say
Bulls Say
Drug Pipeline DevelopmentThe ProfoundBio acquisition provides Genmab with a late-stage asset, Rina-S, that could receive its first approval by 2027, potentially enhancing its product pipeline.
Financial Performance And RatingsAnalyst reiterates a Buy rating with a 12-month price target of $50 per share for the company's stock.
Regulatory MilestonesRina-S received Fast Track Designation from the FDA, with anticipation of additional data in the second half of the year.
Bears Say
Financial PerformanceGenmab recorded diluted net income of DKK66.02 per share, falling short of the forecast diluted net income of DKK78.51 per share.
Market CompetitionThe increasingly competitive landscape in multiple myeloma treatments poses a challenge for GEN3014's market positioning.
Revenue ImpactGMAB Darzalex royalty revenue increased by less than product sales due to lower average exchange rate and an increase in royalty reductions.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
GE91 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €24.40 and its highest was €39.40 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 02, 2024 which is in 7 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 14, 2024. The company reported €0.13 earnings per share for the quarter, missing the consensus estimate of €0.293 by -€0.163.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is €0.16.
How many shares outstanding does Genmab A/S have?
Currently, no data Available
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €0.13 in its last earnings report, missing expectations of €0.293. Following the earnings report the stock price went down -3.937%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Antipodes Partners Ltd. It holds Genmab A/S’s shares valued at 6M.
---
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€37.11 (36.44% Upside)
€37.11 (36.44% Upside)
Blogger Sentiment
Bullish
DE:GE91 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.32%
12-Months-Change
Fundamentals
Return on Equity
14.70%
Trailing 12-Months
Asset Growth
20.34%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GE91 Company Deck
---
GE91 Earnings Call
Q4 2024
0:00 / 0:00
---
GE91 Stock 12 Months Forecast
Average Price Target
€37.11
▲(36.44% Upside)
Technical Analysis
Best Analysts Covering GE91
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-10.57%
reiterated a buy rating 21 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -10.57% per trade.
---